[go: up one dir, main page]

ATE238066T1 - Induktion von immunologischer toleranz unter verwendung von nicht-zellmengeverringernden anti- cd4-antikoepern - Google Patents

Induktion von immunologischer toleranz unter verwendung von nicht-zellmengeverringernden anti- cd4-antikoepern

Info

Publication number
ATE238066T1
ATE238066T1 AT96915808T AT96915808T ATE238066T1 AT E238066 T1 ATE238066 T1 AT E238066T1 AT 96915808 T AT96915808 T AT 96915808T AT 96915808 T AT96915808 T AT 96915808T AT E238066 T1 ATE238066 T1 AT E238066T1
Authority
AT
Austria
Prior art keywords
anticoepers
antip
induction
immunological tolerance
cell quantity
Prior art date
Application number
AT96915808T
Other languages
English (en)
Inventor
Robert W Knowles
Druie E Cavender
Judith M Thomas
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of ATE238066T1 publication Critical patent/ATE238066T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
AT96915808T 1995-05-18 1996-05-16 Induktion von immunologischer toleranz unter verwendung von nicht-zellmengeverringernden anti- cd4-antikoepern ATE238066T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44373995A 1995-05-18 1995-05-18
PCT/US1996/006912 WO1996036359A1 (en) 1995-05-18 1996-05-16 Induction of immunological tolerance by the use of non-depleting anti-cd4 antibodies

Publications (1)

Publication Number Publication Date
ATE238066T1 true ATE238066T1 (de) 2003-05-15

Family

ID=23762005

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96915808T ATE238066T1 (de) 1995-05-18 1996-05-16 Induktion von immunologischer toleranz unter verwendung von nicht-zellmengeverringernden anti- cd4-antikoepern

Country Status (10)

Country Link
EP (2) EP1161955A3 (de)
JP (1) JPH11505251A (de)
AT (1) ATE238066T1 (de)
AU (1) AU715052B2 (de)
CA (1) CA2221350A1 (de)
DE (1) DE69627665T2 (de)
DK (1) DK0840618T3 (de)
ES (1) ES2196150T3 (de)
PT (1) PT840618E (de)
WO (1) WO1996036359A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
WO1998023746A1 (en) * 1996-11-27 1998-06-04 Genentech, Inc. Antibody mutants
WO2002102853A2 (en) * 2001-06-14 2002-12-27 Isis Innovation Limited Cd4-specific antibody trx1 and uses therefor
US7541443B2 (en) 2001-06-14 2009-06-02 Tolerrx, Inc. Anti-CD4 antibodies
EP1460088A1 (de) 2003-03-21 2004-09-22 Biotest AG Humanisierter Antikörper gegen CD4 mit immunsuppressiven Merkmalen
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
TW200902544A (en) 2007-03-13 2009-01-16 Hoffmann La Roche Peptide-complement conjugates
US20090022720A1 (en) 2007-07-20 2009-01-22 Stephan Fischer Conjugate of an antibody against CD4 and antifusogenic peptides
BRPI0909048A2 (pt) 2008-03-13 2015-11-24 Biotest Ag composição farmacêutica, e, método de tratamento de uma doença autoimune
CA2717812A1 (en) 2008-03-13 2009-09-17 Biotest Ag Agent for treating disease
MX2010010026A (es) 2008-03-13 2011-03-21 Biotest Ag Agente para tratar enfermedad.
US8637466B2 (en) 2008-08-11 2014-01-28 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
EP2471543A1 (de) 2010-12-02 2012-07-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Toleranzinduktion oder Immunsuppression zur Verhinderung von insbesondere Transplantat-Wirt-Reaktion (GvHD) durch kurzzeitige Vorinkubation von transplantierten Zellsuspensionen, Geweben oder Organen, die mit Liganden zu Zelloberflächenmolekülen beschichtet sind
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904481A (en) * 1985-04-17 1990-02-27 The Board Of Trustess Of Leland Stanford University Method of conferring immuno-tolerance to a specific antigen
GB8608068D0 (en) * 1986-04-02 1986-05-08 Cobbold S P Monoclonal antibodies
GB8912497D0 (en) * 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation

Also Published As

Publication number Publication date
EP1161955A3 (de) 2001-12-19
DE69627665D1 (de) 2003-05-28
ES2196150T3 (es) 2003-12-16
AU5747996A (en) 1996-11-29
WO1996036359A1 (en) 1996-11-21
DE69627665T2 (de) 2004-02-19
DK0840618T3 (da) 2003-08-11
PT840618E (pt) 2003-08-29
AU715052B2 (en) 2000-01-13
CA2221350A1 (en) 1996-11-21
EP0840618B1 (de) 2003-04-23
EP0840618A1 (de) 1998-05-13
JPH11505251A (ja) 1999-05-18
EP1161955A2 (de) 2001-12-12

Similar Documents

Publication Publication Date Title
ATE238066T1 (de) Induktion von immunologischer toleranz unter verwendung von nicht-zellmengeverringernden anti- cd4-antikoepern
GR3023252T3 (en) Framework mutated antibodies and their preparation
AU5055593A (en) Antibodies specific for HIV
IL143596A0 (en) Vascular endothelial cell growth factor antagonists and uses thereof
ATE224184T1 (de) Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
EP0539970A3 (en) Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby
GB9318911D0 (en) Recombinant antibody and method
ATE52141T1 (de) Immuntest, mittel und verfahren zur bestimmung von natuerlichem und ungewoehnlichem humanprothrombin.
ATE101876T1 (de) Verfahren zur verringerung der heterogenitaet von monoklonalen antikoerpern.
DE50114906D1 (de) Verwendung cd28 spezifischer monoklonaler antikörper zur stimulation von blutzellen, welche kein cd28 tragen
ATE287949T1 (de) Löslicher komplex morphogener proteine und zusammensetzungen davon
ATE58172T1 (de) Monoklonale antikoerper gegen alpha-2 interferon und hybridomas, die solche antikoerper produzieren.
DE3787706D1 (de) Verfahren zur quantitativen Bestimmung der Antigene und Antikörper.
EP0642333A4 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion.
FR2701953B1 (fr) Protéine de fusion multi-VIP et procédé de préparation de VIP recombinant.
DE3570677D1 (en) Acino-foetal differentiation proteins associated with cancer of the pancreas, antiserum and monoclonal antibodies against these proteins and processes for their preparation
DE3785175D1 (de) A-assoziierte h-antigene, spezifische monoklonale antikoerper und methoden zu deren verwendung zur blutgruppenbestimmung.
ATE58397T1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
DE3874445D1 (de) Verfahren zur herstellung von schalentierextrakt-konzentraten und schalentierextrakt-konzentrate.
ATE125306T1 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.
DE68901559D1 (de) Verfahren und mittel zur augenanaesthesie unter verwendung von rodocain.
DE3671603D1 (de) Verfahren zur zucht von babesia canis, verwendung zur herstellung von antigenen und impfstoffen und antigene und impfstoffe gegen piroplasmose.
DE3650468D1 (de) Methoden zur Verwendung von an humanen Klasse-II-Histokompatibilitätsantigenen mangelnden Zellinien
DE3887124D1 (de) VERFAHREN ZUR BESTIMMUNG VON IgM-ANTIKÖRPERN.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0840618

Country of ref document: EP

REN Ceased due to non-payment of the annual fee